- Home
- LPSN vs IFRX Comparison
LPSN vs IFRX Comparison
Compare LPSN & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPSN
- IFRX
- Stock Information
- Founded
- LPSN 1995
- IFRX 2007
- Country
- LPSN United States
- IFRX Germany
- Employees
- LPSN N/A
- IFRX N/A
- Industry
- LPSN EDP Services
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- LPSN Technology
- IFRX Health Care
- Exchange
- LPSN Nasdaq
- IFRX Nasdaq
- Market Cap
- LPSN 108.1M
- IFRX 117.8M
- IPO Year
- LPSN 2000
- IFRX 2017
- Fundamental
- Price
- LPSN $1.17
- IFRX $1.83
- Analyst Decision
- LPSN Hold
- IFRX Strong Buy
- Analyst Count
- LPSN 6
- IFRX 1
- Target Price
- LPSN $1.18
- IFRX $8.00
- AVG Volume (30 Days)
- LPSN 2.2M
- IFRX 498.3K
- Earning Date
- LPSN 03-05-2025
- IFRX 03-20-2025
- Dividend Yield
- LPSN N/A
- IFRX N/A
- EPS Growth
- LPSN N/A
- IFRX N/A
- EPS
- LPSN N/A
- IFRX N/A
- Revenue
- LPSN $334,736,000.00
- IFRX $187,930.00
- Revenue This Year
- LPSN N/A
- IFRX $396.02
- Revenue Next Year
- LPSN N/A
- IFRX $155.22
- P/E Ratio
- LPSN N/A
- IFRX N/A
- Revenue Growth
- LPSN N/A
- IFRX 177.12
- 52 Week Low
- LPSN $0.45
- IFRX $1.17
- 52 Week High
- LPSN $2.73
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- LPSN 41.48
- IFRX 32.97
- Support Level
- LPSN $1.20
- IFRX $1.76
- Resistance Level
- LPSN $1.37
- IFRX $1.98
- Average True Range (ATR)
- LPSN 0.09
- IFRX 0.19
- MACD
- LPSN -0.03
- IFRX -0.08
- Stochastic Oscillator
- LPSN 6.06
- IFRX 6.65
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation.. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.